A retrospective study of 657 women with vaginal intraepithelial neoplasia (VaIN)

Vaginal intraepithelial neoplasia (VaIN) is frequently underdiagnosed. The aim of this study was to explore the clinical characteristics of patients with VaIN and identify more sensitive diagnostic methods. This study retrospectively analyzed 657 patients with VaIN from the International Peace Maternal and Child Health Hospital during a ten-year period. Among the 657 patients, 26.5% were diagnosed with VaIN 2/3. The proportions of patients with VaIN 2/3 among those who did and did not undergo hysterectomy were 39.5% and 24.7%, respectively. The sensitivity of cytology testing for VaIN in those with only VaIN, VaIN concomitant with cervical or vulvar lesions, and posthysterectomy VaIN was 56.7%, 66.5%, and 72.3%, respectively. The sensitivity of high-risk human papillomavirus (hrHPV) testing for VaIN in the same categories was 87.7%, 86.5%, and 74.3%, respectively. The sensitivity of cytology and hrHPV cotesting for VaIN in the same categories was 95.2%, 95.6%, and 95.0%, respectively. In patients with VaIN 2/3, the incidence of HPV 16/18 was 50.6%. However, in patients with VaIN 1, the incidence of HPV 16/18 was only 22.6 %. The severity of VaIN was associated with HPV genotyping and hysterectomy, but not with concomitant cervical or vulvar lesions. A combination of cytology and hrHPV could increase the sensitivity of the diagnosis of VaIN. HPV 16 and 18 are the most frequent HPV-types in VaIN 2/3. Twelve specific hrHPV subtypes were the main virus types associated with the development of VaIN 1.

Carcinoma in situ; Human papilloma viruses; Hysterectomy; Vaginal neoplasms

[1] Adhikari P, Vietje P, Mount S. Premalignant and malignant lesions of the vagina. Diagnostic Histopathology. 2017; 23: 28–34.

[2] Alfonzo E, Holmberg E, Sparén P, Milsom I, Strander B. Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. BJOG. 2020; 127: 448–454.

[3] Cao D, Wu D, Xu Y. Vaginal intraepithelial neoplasia in patients after total hysterectomy. Current Problems in Cancer. 2021; 45: 100687.

[4] Chao A, Jao M, Huang C, Huang H, Cheng H, Yang J, et al. Human papillomavirus genotype in cervical intraepithelial neoplasia grades 2 and 3 of Taiwanese women. International Journal of Cancer. 2011; 128: 653–659.

[5] Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstetrics & Gynecology. 2009; 113: 917–924.

[6] De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International Journal of Cancer. 2009; 124: 1626–1636.

[7] Sopracordevole F, Barbero M, Clemente N, Fallani MG, Cattani P, Agarossi A, et al. High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian society of colposcopy and cervico-vaginal pathology (SICPCV). European Review for Medical and Pharmacological Sciences. 2016; 20: 818–824.

[8] Cong Q, Song Y, Wang Q, Zhang H, Gao S, Sui L. A retrospective study of cytology, high-risk HPV, and colposcopy results of vaginal intraepithelial neoplasia patients. BioMed Research International. 2018; 2018: 1–6.

[9] Gurumurthy M, Leeson S, Tidy J, Cruickshank ME. UK national survey of the management of vaginal intraepithelial neoplasia. Journal of Obstetrics and Gynaecology. 2020; 40: 694–698.

[10] Dodge JA, Eltabbakh GH, Mount SL, Walker RP, Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecologic Oncology. 2001; 83: 363–369.

[11] Ao M, Zheng D, Wang J, Gu X, Xi M. A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients. Journal of Medical Virology. 2022; 94: 737–744.

[12] Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Reviews in Obstetrics & Gynecology. 2008; 1: 2–10.

[13] Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. European Journal of Cancer. 2014; 50: 2846–2854.